EUVIMEDEUVIMED entdecken
EditorialKommentar

Fit for the fight: BTK inhibitors prime CAR T cells in CLL

John G Gribben iD

Blood · 12.11.2026 · 148 (20) · 2437-2439

DOI: 10.1182/blood.2026035633 ↗

Kurz gefasst

Editorial in der Zeitschrift Blood, erschienen am 12.11.2026. Verfasst von John G Gribben. Beteiligte Einrichtung: Queen Mary University of London. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this issue of Blood, Wierda et al 1 report the primary analysis of the ibrutinib combination cohort of the phase 1/2 TRANSCEND CLL 004 study, demonstrating that concurrent ibrutinib and lisocabtagene maraleucel (lisocel) produce deep, durable responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).Although differences in study design and patient populations preclude direct comparisons between cohorts, propensity scoring analysis supports that ibrutinib plus liso-cel demonstrated better efficacy and safety than the liso-cel monotherapy arm in this study, although the study was not designed or powered to test this hypothesis.This study provides strong clinical support for a concept emerging over the past decade: that successful chimeric antigen receptor (CAR) T-cell therapy depends not only on receptor engineering but also on the biological fitness of the T cells that are collected, manufactured, and subsequently reinfused.CAR T-cell therapy has transformed the treatment of B-cell malignancies, yet its impact on CLL has lagged behind the remarkable success observed in other B-cell lymphomas.This disparity is unlikely to reflect differences in CD19, the target antigen, but rather highlights that one of the defining biological features of CLL is a profoundly dysfunctional immune system.Chronic antigen stimulation, persistent inflammation, and repeated therapies result in T cells with impaired proliferative capacity, defective immune synapse formation, increased expression of inhibitory receptors, such as CD279, programmed cell death protein 1 (PD-1) and CD66, and T-cell immunoglobulin and mucin domain containing protein 3 (TIM-3), and features of terminal exhaustion.[2][3][4] Engineering these cells to express a CAR T-cell product cannot completely overcome these intrinsic defects.

Autor:innen und Institutionen

  • Queen Mary University of London.

ORCID-Profile: John G Gribben

Zitieren

APA

Gribben, J. G. (2026). Fit for the fight: BTK inhibitors prime CAR T cells in CLL. Blood, 148(20), 2437-2439. https://doi.org/10.1182/blood.2026035633

Vancouver

Gribben JG. Fit for the fight: BTK inhibitors prime CAR T cells in CLL. Blood. 2026;148(20):2437-2439. doi:10.1182/blood.2026035633

BibTeX
@article{Gribben2026,
  author = {Gribben, John G},
  title = {Fit for the fight: BTK inhibitors prime CAR T cells in CLL},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {20},
  pages = {2437--2439},
  doi = {10.1182/blood.2026035633}
}
Kostenlos starten →